about
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's diseaseIrritable bowel syndrome and chronic constipation: Fact and fictionOverlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndromeLoss-of-Function of the Voltage-Gated Sodium Channel NaV1.5 (Channelopathies) in Patients With Irritable Bowel SyndromeConstipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation.Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapyRole of faecal calprotectin as non-invasive marker of intestinal inflammation.Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders.Nomenclature and diagnosis of gluten-related disorders: A position statement by the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO).Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome.Velusetrag for the treatment of chronic constipation.How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?An extended assessment of bowel habits in a general populationRandomised controlled trial of mesalazine in IBS.Radionuclide evaluation of the lower gastrointestinal tract.The genetics of the serotonin transporter and irritable bowel syndrome.Optimal treatment of laryngopharyngeal reflux disease.Duloxetine in panic disorder with somatic gastric pain.Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model.The female pelvic floor through midlife and aging.Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome.Diagnosis and treatment of faecal incontinence: Consensus statement of the Italian Society of Colorectal Surgery and the Italian Association of Hospital Gastroenterologists.Prucalopride succinate for the treatment of constipation: an update.Bioelectrical impedance vector analysis in patients with irritable bowel syndrome on a low FODMAP diet: a pilot study.Prucalopride: For functional constipation only?Practice guidelines on the use of esophageal manometry - A GISMAD-SIGE-AIGO medical position statement.Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts.Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn.Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome.Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD.Neuroendocrine Dysregulation in Irritable Bowel Syndrome Patients: A Pilot StudyAssociation between baseline impedance values and response proton pump inhibitors in patients with heartburn.Enteric glial cells counteract Clostridium difficile Toxin B through a NADPH oxidase/ROS/JNK/caspase-3 axis, without involving mitochondrial pathways.Consensus statement AIGO/SICCR: diagnosis and treatment of chronic constipation and obstructed defecation (part I: diagnosis).Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.Subthreshold Psychiatric Psychopathology in Functional Gastrointestinal Disorders: Can It Be the Bridge between Gastroenterology and Psychiatry?Relationship of TT virus and Helicobacter pylori infections in gastric tissues of patients with gastritis.Neuroendocrine markers and psychological features in patients with irritable bowel syndrome.Increased prevalence of rare sucrase-isomaltase (SI) pathogenic variants in irritable bowel syndrome patients.
P50
Q24685692-DE335AAD-828B-469F-88CE-BD43D21E5879Q26777547-AE27D282-A54B-486A-AC7C-719486EB8F72Q27008998-141B24DD-D400-49E7-A5E6-ED118F0046DEQ29544671-9D2D3BD0-2770-497B-8CFA-9DAB2F36953CQ33695627-D253EFD3-85FE-4786-A085-ADB91A40B228Q33958808-0FB865CB-ACF5-4193-A57A-C558E3FFDA81Q34270506-E0CE09B7-1CF0-42C1-8E8F-C1F8E1B4BB48Q34473834-116C8D68-66C4-48FC-AAB0-CCBED18045F8Q34545909-8CB984F4-ED0C-46F1-BE66-504F1613ACFAQ34580877-58EAC6A3-9700-4646-AC0B-F53D2FB83B89Q36042950-33F7D01C-7A14-41EF-82FA-BC25E70BFD2AQ36215530-E4C6DF54-D4C7-481B-AC1D-4795104C81BFQ36474156-EAC66EAB-4797-4262-8BBE-3FB2A208FAE3Q36475502-19BD8E55-F9BF-472C-B94E-9A1BB74CD1CFQ37138783-D0A6845B-1451-42A0-BDEB-3CFDD8AFD0A3Q37190229-58FFB806-3B0F-421D-BDC9-57C9722DB4D8Q37253915-3318AAA6-4C03-4AB0-9E4C-BC0C78F3A67EQ37347060-5212D2F6-517F-4A49-8968-D5CA6558C765Q38024260-F4FB4163-EF4A-4717-864B-B04783DA24D1Q38140414-D2674A7E-E9AE-4047-9F0F-A156BE3B956DQ38178543-CE2409EE-ABE0-4FD4-9310-54425EDBCB9DQ38456780-8C81D7FB-E8D9-4B53-97E2-906EA13659D9Q38662841-07415923-AD7B-41C4-858B-A8451D346317Q38752125-7580C94C-AB38-4ACC-B452-C85A290AB394Q38833279-8A20F36D-FFE3-4C47-894B-AF4552101E9BQ38904580-9B5A047D-126B-40FE-80A7-F810B77B673CQ39124540-23E9A0B0-FA14-4E82-B009-56C0A3B958D9Q39213473-58CE4506-48F1-492E-87E6-842DF2852270Q39221366-DD97990C-A893-4641-AEEF-31D70E808D14Q40463272-AB57B0C4-9C25-41F7-85F0-88D0F0BA2054Q40575149-2CAB6D7E-6D5D-4018-A47C-929A31859873Q40969307-BF4FB5A6-B81E-49AE-8B51-DF4CADACD1C1Q41699373-8DA92210-F74C-4AD0-A854-1EA2A1038FB1Q42372011-01DECBA9-8CA7-450A-8B1A-AC717626F202Q42547946-EB876608-506B-4212-B637-FA0A6B4AA9BDQ44700991-815A15A1-2775-445A-9699-E4DE43205E23Q45471839-79CAAE5B-4E33-47D6-97A2-FA94B3AB543EQ45722618-BA5BB2C6-86FA-48D6-A7E3-84680ADD2A3BQ48178534-96534E2F-F690-4F71-88FD-EAC76F4433EAQ50148815-6F0CA077-4570-424B-822D-0E5D777FCD91
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Massimo Bellini
@ast
Massimo Bellini
@en
Massimo Bellini
@es
Massimo Bellini
@nl
type
label
Massimo Bellini
@ast
Massimo Bellini
@en
Massimo Bellini
@es
Massimo Bellini
@nl
altLabel
massimo bellini
@en
prefLabel
Massimo Bellini
@ast
Massimo Bellini
@en
Massimo Bellini
@es
Massimo Bellini
@nl
P106
P1153
7102558310
P21
P31
P496
0000-0002-6387-6443